Last updated: July 20, 2026
GENENTECH, INC. v. SUN PHARMACEUTICAL INDUSTRIES, LTD (2:24-cv-10567): Litigation Summary, Patent Issues, and Timeline
Executive summary: No litigation summary can be produced from the provided case identifier alone. A complete and accurate analysis requires the case’s docket details (claims asserted, asserted patents and expiration dates, motions and rulings, parties’ positions, and any settlement or FDA-linked conduct). Without those specifics, any account of what patents are at issue or how the dispute evolved would be incomplete.
What is GENENTECH, INC. v. SUN PHARMACEUTICAL INDUSTRIES, LTD 2:24-cv-10567 about (and what patents are asserted)?
Answer: Not determinable from the case number alone.
What claims typically drive these disputes (for context)
- Paragraph IV ANDA patent infringement for small molecules.
- Orange Book listing disputes.
- Injunction requests under 35 U.S.C. § 271(e)(2) tied to FDA approval timelines.
- Issues of infringement, invalidity, and eligibility of asserted claims.
What to extract from the complaint and answer
- Asserted patent numbers and claim sets.
- Alleged commercial product(s) and ANDA/BLA or other FDA application linkage.
- Infringement theory (literal infringement vs doctrine of equivalents).
- Defendant’s invalidity grounds (anticipation, obviousness, indefiniteness, improper subject matter).
- Case posture (venue, jurisdiction, timeliness, infringement allegations sufficientness).
What procedural milestones and hearings occurred in 2:24-cv-10567?
Answer: Not determinable from the case number alone.
Milestones that typically matter in IP dockets
- Complaint filing date and service.
- Rule 26 scheduling and early infringement contentions.
- Markman schedule (if claim construction is sought).
- Claim construction order dates.
- Summary judgment decisions.
- Trial dates or vacated settings.
How strong is Genentech’s patent estate in this case: what are the asserted patent expiration risks?
Answer: Not determinable without the asserted patent numbers, their prosecution history, and claim scope.
What determines “strength” in court outcomes
- Claim construction outcomes.
- Prior art density for the asserted claims.
- Whether the patents are method-of-use vs composition vs formulation vs manufacturing.
- Remaining term and the likelihood of remaining claims surviving invalidity.
Which patents are likely Orange Book-listed and how does that impact the case?
Answer: Not determinable without the FDA linkage (Orange Book listing for the specific reference product, the listed patents, and the statutory bases).
Orange Book mechanics relevant to litigation
- Listed patents are grouped by regulatory type (drug substance, drug product, method of use).
- ANDA or 505(b)(2) applicants must certify to each listed patent (Paragraph I-IV).
- Suit is typically timed to the 30-month stay and the FDA approval pathway.
What Paragraph IV issues or 30-month stay questions are at play in 2:24-cv-10567?
Answer: Not determinable from the case number alone.
What the court usually decides
- Whether the asserted claims are infringed by the proposed generic/biosimilar.
- Whether claims are invalid under 35 U.S.C. §§ 102, 103, 112.
- Whether claims meet statutory eligibility and definiteness requirements.
- Whether the case qualifies for typical case management and expedited treatment.
What generic entry risks exist for Sun Pharmaceutical based on 2:24-cv-10567?
Answer: Not determinable without the FDA status for the relevant application and the current injunction posture.
What drives launch timing in practice
- Remaining exclusivity (data exclusivity, patent exclusivity where applicable).
- Pending injunctions or denial of injunctive relief.
- Settlement terms (authorized generic dates, carveouts, license scope).
- Any FDA approval date and designations for market entry.
Has the case settled or moved toward an injunction or dismissal?
Answer: Not determinable from the case number alone.
Settlement terms that materially affect competition
- Nonsuit, covenant-not-to-sue, or mutual release scope.
- Launch date carveouts and royalty arrangements.
- Conditions tied to labeling, manufacturing process changes, or exclusivity carveouts.
- Dismissal with prejudice vs without prejudice and any retained enforcement rights.
How does this case compare with other Genentech vs Sun Pharma IP disputes?
Answer: Not determinable without the asserted product/patents and the specific litigation posture.
What a valid comparison requires
- Same reference product and same therapeutic indication.
- Same patent family versus different patent families.
- Similar claim types (composition vs method of use).
- Similar claim constructions and invalidity theories.
Key Takeaways
- A litigation summary and analysis cannot be produced from the identifier “2:24-cv-10567” alone.
- Any accurate assessment depends on docket facts: asserted patents, FDA linkage, procedural history, and rulings or settlement terms.
FAQs
- What information on the docket is required to summarize patent infringement issues in 2:24-cv-10567?
- How do claim construction outcomes typically influence the strength of an ANDA Paragraph IV case?
- What settlement structures most often define launch timing in Genentech-type Hatch-Waxman disputes?
- How does remaining patent term and Orange Book listing type affect injunction scope?
- What milestones signal whether an expedited patent case will resolve by summary judgment or trial?
References
No sources can be cited because the underlying docket and filings were not provided.
